

Lockington, Elliott (SPAC/PSPC)

From: Roy, Cecely (SPAC/PSPC)
Sent: September 28, 2020 3:26 PM
To: Gerasimov, Boyan (SPAC/PSPC); fitz-morris, James (SPAC/PSPC)
Cc: Lockington, Elliott (SPAC/PSPC); Mullan-Boudreau, Caitlin (SPAC/PSPC); Kusnick, Chelsea (SPAC/PSPC); Church, Leslie (SPAC/PSPC)
Subject: RE: FOR REVIEW - QA for Abbott ID Now Announcement
Importance: High
Categories: Red Category

Hi there –

I have basically answered all of the questions in the QA, apart from a few highlighted in blue:
https://docs.google.com/document/d/1YjEUEltlgdc_vZ8k7t4yZKM6UDVbGfdl1HspFAMgml8/edit?usp=sharing

@ Boyan & James – if you can please review this QA as soon as possible that would be much appreciated. If we are on for tomorrow, I will need to get this to the Minister asap.

Thank you,
Cecely

From: Roy, Cecely (SPAC/PSPC)
Sent: September 28, 2020 12:03 PM
To: Gerasimov, Boyan (SPAC/PSPC) <boyan.gerasimov@canada.ca>; Church, Leslie (SPAC/PSPC) <leslie.church@canada.ca>
Cc: fitz-morris, James (SPAC/PSPC) <james.fitz-morris@canada.ca>; Lockington, Elliott (SPAC/PSPC) <elliott.lockington@canada.ca>; Mullan-Boudreau, Caitlin (SPAC/PSPC) <caitlin.mullan-boudreau@canada.ca>
Subject: FOR REVIEW - QA for Abbott ID Now Announcement

Hi team,

The department put together a QA for the Abbott announcement tomorrow – yay! (Attached)

But, I do still have some technical questions I am wondering if we would know in MINO or can engage Health mino on.. My questions include those below, which are also in the [Google doc](#) of the draft QA that I just shared with you. I'd also be happy to get questions added here that I haven't thought of.

Thanks,
Cecely

<< File: PSPC_QandAs-Abbott_2020-09-27 (1145am).docx >>
//

Health

(Minister Hajdu may not be at the presser)

1. **What is the distribution plan with these tests? Where are they targeted for, what will they be used for? Will they replace PCR testing?**
2. **Where will they go - which jurisdictions – which PTs get these first?**
3. **Who gets these? Testing centres, schools, airports, workplaces or individuals?**
4. **Will the administration of these tests require additional testing sites to be set up as they have in NYC?**
5. **Do they still need to be administered by a healthcare professional or can these work at home or in a work setting?**
6. **Was the purchase of these tests made at the recommendation the Public Health Agency?**

7. Given the FDA has voiced their concerns over the efficacy of this particular test, why is Canada purchasing it, particularly since it has not received HC approval?

Does one test = one person?

What is the percentage of efficacy?

**Are you taking delivery of the kits and analyzers before they are approved?
What happens to your investment and the test kits if they aren't approved by HC?**

Why have you only ordered 7.9 million?

Can we get more? If so, when?

Are you also looking at the Binax now test as well?

Why don't you have an agreement with Cepheid or Roche?

Are you looking to purchase the Hyris bCUBE given it has actually been approved by Health Canada?

What is happening with the other tests that Canada had previously procured?

(In addition to these rapid tests from Abbott, the Government of Canada has previously signed agreements for rapid tests, from Biomerieux (up to 699,750 tests) and InterMedico (1.2 million GeneExpert tests).)